Navigation Links
Cephalon Recommends Shareholders Reject Valeant Nominees
Date:4/7/2011

t solicitation statement with the SEC in connection with its proposed consent solicitation.  In the interests of allowing consideration of this matter on a timely basis by Cephalon's shareholders and significant participation in the process by Cephalon's many long-term shareholders, pursuant to the Company's by-laws, the Cephalon Board of Directors has set a record date for the consent solicitation of Friday, April 8, 2011.  The consent solicitation period will last for 60 days from the date of the earliest dated consent delivered to the Company.

Deutsche Bank Securities Inc. and BofA Merrill Lynch are acting as financial advisors and Skadden, Arps, Slate, Meagher & Flom LLP is acting as Cephalon's legal counsel.

About Cephalon, Inc.

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world.  Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.  Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide.  The company sells numerous branded and generic products around the world.  In total, Cephalon sells more than 150 products in nearly 100 countries.  More information on Cephalon and its products is available at http://www.cephalon.com/.

Additional Information:

Cephalon, Inc. (the "Company"), its directors and certain of its officers and employees may be deemed to be participants in the solicitation of consent revocations from stockholders in connection with a consent solicitation by Valeant Pharmaceuticals International, Inc. ("Valeant") to replace the Company's current Board of Dire
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cephalon First Quarter 2011 Earnings Conference Call Tuesday, May 3, 2011 at 5:00 p.m. EDT
2. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
3. Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D.
4. Cephalon Mourns the Passing of Founder, Chairman and CEO, Frank Baldino Jr., Ph.D.
5. Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
6. Cephalon Reports Record Earnings and Raises 2010 Guidance
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
9. Cephalon Completes Acquisition of Arana Therapeutics
10. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
11. Cephalon Quarterly Conference Call Invitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015 According to a new ... (Mesh/Tissue patch, Allograft, Xenograft, Suture Anchor, Interference Screws, Laparoscopic ... Breast augmentation) - Global Forecast to 2019", published by ... reach $14.7 Billion in 2019 from $10.3 Billion in ... to 2019. Browse 70 market data ...
(Date:3/6/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... Poyhonen , the Company,s President and Chief Executive Officer, ... Chief Financial Officer, will present an overview of Senomyx,s ... at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time) ...
(Date:3/5/2015)... NEW YORK , March 5, 2015  DuPont ... J.P. Morgan Aviation, Transportation and Industrials Conference held today ... Vice President Matthew L. Trerotola discussed strategy, ... Advanced Materials segments for DuPont.  Strengthening and growing the ... of the three areas of strategic priority for DuPont. ...
(Date:3/5/2015)... BioPlus Specialty Pharmacy (BioPlus) announces the hiring ... of Managed Care. In this role, Damm will build ... nation’s leading specialty pharmacies. , Damm, who is based ... pharmacy and biotech experience to his new position with ... and Pfizer. Prior to working in Healthcare Damm served ...
Breaking Biology Technology:Soft Tissue Repair Market worth $14.7 Billion in 2019 2Soft Tissue Repair Market worth $14.7 Billion in 2019 3Soft Tissue Repair Market worth $14.7 Billion in 2019 4SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2
... Feb. 12 Pharmacyclics, Inc.,(Nasdaq: PCYC ), ... clinical testing and several late stage preclinical programs,announced today ... new board,member. , Robert W. ... CEO of the,company after acting as interim CEO for ...
... Company Exceeds Sales and Earnings GuidanceCompany Reiterates 2009 Earnings ... 12 Cephalon, Inc . (Nasdaq: ... $1.943 billion, compared to sales of $1.727 billion for ... income per common share for the full year 2008 ...
... Inc., announced,today the appointment of John P. Walker as ... of Directors. Walker was most recently the,Chairman and ... in January 2009. , (Photo: ... Bio is focused on the development of induced pluripotent ...
Cached Biology Technology:Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 2Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 3Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 4Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 5Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 6Cephalon's New Product Launches Pace Record 2008 Sales 2Cephalon's New Product Launches Pace Record 2008 Sales 3Cephalon's New Product Launches Pace Record 2008 Sales 4Cephalon's New Product Launches Pace Record 2008 Sales 5Cephalon's New Product Launches Pace Record 2008 Sales 6Cephalon's New Product Launches Pace Record 2008 Sales 7Cephalon's New Product Launches Pace Record 2008 Sales 8Cephalon's New Product Launches Pace Record 2008 Sales 9Cephalon's New Product Launches Pace Record 2008 Sales 10Cephalon's New Product Launches Pace Record 2008 Sales 11Cephalon's New Product Launches Pace Record 2008 Sales 12Cephalon's New Product Launches Pace Record 2008 Sales 13Cephalon's New Product Launches Pace Record 2008 Sales 14Cephalon's New Product Launches Pace Record 2008 Sales 15Cephalon's New Product Launches Pace Record 2008 Sales 16Cephalon's New Product Launches Pace Record 2008 Sales 17Cephalon's New Product Launches Pace Record 2008 Sales 18Cephalon's New Product Launches Pace Record 2008 Sales 19Cephalon's New Product Launches Pace Record 2008 Sales 20Cephalon's New Product Launches Pace Record 2008 Sales 21iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer 2
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... Aug. 5, 2013 - For a new study in ... how different concentrations of lipids affect growth performance in ... of lipids affect pigs. According to the researchers, ... absorption because swine genetics have improved over the years. ...
... University of Illinois scientists have evidence that lifelong exposure ... colon cancer by repressing a signal that leads to accelerated ... our study, we report a change in the expression of ... Chen, a U of I professor of food science and ...
... interact with one anotherand not just today. Scientists are studying ... the world in the ancient past and to identify ways ... to a new study published in the August 2 issue ... throughout Earth,s history, but the recent rate of global warming ...
Cached Biology News:Researchers re-evaluate swine nutrition 2Scientists learn how soy foods protect against colon cancer 2Looking to the past to predict the future of climate change 2